Eli Lilly and Company (NYSE:LLY) is Walter & Keenan Wealth Management LLC IN ADV’s Largest Position

Walter & Keenan Wealth Management LLC IN ADV lessened its position in shares of Eli Lilly and Company (NYSE:LLY) by 1.0% during the 3rd quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 25,488 shares of the company’s stock after selling 258 shares during the quarter. Eli Lilly and Company comprises approximately 6.9% of Walter & Keenan Wealth Management LLC IN ADV’s portfolio, making the stock its largest position. Walter & Keenan Wealth Management LLC IN ADV’s holdings in Eli Lilly and Company were worth $22,581,000 at the end of the most recent quarter.

A number of other large investors have also recently added to or reduced their stakes in LLY. Adell Harriman & Carpenter Inc. raised its holdings in Eli Lilly and Company by 19.6% in the 3rd quarter. Adell Harriman & Carpenter Inc. now owns 11,659 shares of the company’s stock valued at $10,330,000 after buying an additional 1,910 shares during the period. Childress Capital Advisors LLC increased its position in shares of Eli Lilly and Company by 4.5% during the third quarter. Childress Capital Advisors LLC now owns 2,445 shares of the company’s stock valued at $2,166,000 after acquiring an additional 105 shares during the last quarter. Highview Capital Management LLC DE raised its stake in shares of Eli Lilly and Company by 2.7% in the 3rd quarter. Highview Capital Management LLC DE now owns 6,763 shares of the company’s stock valued at $5,992,000 after acquiring an additional 181 shares during the period. Lodestar Private Asset Management LLC lifted its holdings in shares of Eli Lilly and Company by 17.6% in the 3rd quarter. Lodestar Private Asset Management LLC now owns 1,003 shares of the company’s stock worth $888,000 after acquiring an additional 150 shares during the last quarter. Finally, Jacobsen Capital Management boosted its position in shares of Eli Lilly and Company by 1.9% during the 3rd quarter. Jacobsen Capital Management now owns 1,282 shares of the company’s stock worth $1,136,000 after purchasing an additional 24 shares during the period. 82.53% of the stock is currently owned by institutional investors and hedge funds.

Eli Lilly and Company Stock Down 6.3 %

Shares of NYSE LLY opened at $846.90 on Thursday. The business has a 50-day moving average of $916.20 and a two-hundred day moving average of $865.10. The company has a market capitalization of $804.90 billion, a price-to-earnings ratio of 124.73, a price-to-earnings-growth ratio of 3.24 and a beta of 0.42. Eli Lilly and Company has a 1 year low of $547.61 and a 1 year high of $972.53. The company has a debt-to-equity ratio of 1.74, a current ratio of 1.11 and a quick ratio of 0.87.

Eli Lilly and Company (NYSE:LLY) last posted its earnings results on Wednesday, October 30th. The company reported $1.18 earnings per share for the quarter, missing the consensus estimate of $1.53 by ($0.35). The business had revenue of $11.44 billion for the quarter, compared to analysts’ expectations of $12.09 billion. Eli Lilly and Company had a return on equity of 67.52% and a net margin of 18.86%. Eli Lilly and Company’s revenue for the quarter was up 20.4% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $0.10 EPS. On average, analysts forecast that Eli Lilly and Company will post 14.05 earnings per share for the current fiscal year.

Eli Lilly and Company Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Tuesday, December 10th. Investors of record on Friday, November 15th will be given a $1.30 dividend. This represents a $5.20 dividend on an annualized basis and a dividend yield of 0.61%. The ex-dividend date is Friday, November 15th. Eli Lilly and Company’s dividend payout ratio (DPR) is 76.58%.

Analyst Ratings Changes

A number of analysts have issued reports on LLY shares. Citigroup boosted their target price on Eli Lilly and Company from $1,060.00 to $1,250.00 and gave the company a “buy” rating in a research report on Friday, October 25th. Truist Financial boosted their price objective on Eli Lilly and Company from $1,000.00 to $1,033.00 and gave the company a “buy” rating in a report on Thursday, October 10th. BMO Capital Markets raised their target price on Eli Lilly and Company from $1,001.00 to $1,101.00 and gave the company an “outperform” rating in a report on Friday, August 9th. Guggenheim boosted their price target on shares of Eli Lilly and Company from $884.00 to $1,030.00 and gave the stock a “buy” rating in a research note on Friday, August 16th. Finally, Barclays raised their price objective on shares of Eli Lilly and Company from $913.00 to $1,025.00 and gave the company an “overweight” rating in a research note on Wednesday, July 10th. Three investment analysts have rated the stock with a hold rating and seventeen have assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, Eli Lilly and Company has a consensus rating of “Moderate Buy” and a consensus price target of $1,013.41.

About Eli Lilly and Company

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.